KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Common Equity (2016 - 2025)

Historic Common Equity for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $917.3 million.

  • Acadia Pharmaceuticals' Common Equity rose 5892.3% to $917.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $917.3 million, marking a year-over-year increase of 5892.3%. This contributed to the annual value of $732.8 million for FY2024, which is 6972.43% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Common Equity is $917.3 million, which was up 5892.3% from $822.4 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Common Equity's 5-year high stood at $917.3 million during Q3 2025, with a 5-year trough of $362.2 million in Q3 2023.
  • Moreover, its 5-year median value for Common Equity was $516.7 million (2024), whereas its average is $543.1 million.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Common Equity plummeted by 2597.2% in 2022 and then skyrocketed by 6972.43% in 2024.
  • Acadia Pharmaceuticals' Common Equity (Quarter) stood at $540.9 million in 2021, then dropped by 25.97% to $400.4 million in 2022, then rose by 7.83% to $431.8 million in 2023, then soared by 69.72% to $732.8 million in 2024, then increased by 25.17% to $917.3 million in 2025.
  • Its Common Equity was $917.3 million in Q3 2025, compared to $822.4 million in Q2 2025 and $765.2 million in Q1 2025.